Vis enkel innførsel

dc.contributor.authorHolmøy, Trygve
dc.contributor.authorHøglund, Rune Alexander
dc.contributor.authorIlles, Zsolt
dc.contributor.authorMyhr, Kjell-Morten
dc.contributor.authorTorkildsen, Øivind
dc.PublishedJournal of Neurology. 2020, 1-15.
dc.description.abstractBackground Treatment of neuromyelitis optica spectrum disorder (NMOSD) has so far been based on retrospective case series. The results of six randomized clinical trials including five different monoclonal antibodies targeting four molecules and three distinct pathophysiological pathways have recently been published. Methods Literature search on clinical trials and case studies in NMOSD up to July 10. 2020. Results We review mechanism of action, efficacy and side effects, and consequences for reproductive health from traditional immunosuppressants and monoclonal antibodies including rituximab, inebilizumab, eculizumab, tocilizumab and satralizumab. Conclusion In NMOSD patients with antibodies against aquaporin 4, monoclonal antibodies that deplete B cells (rituximab and inebilizumab) or interfere with interleukin 6 signaling (tocilizumab and satralizumab) or complement activation (eculizumab) have superior efficacy compared to placebo. Tocilizumab and rituximab were also superior to azathioprine in head-to-head studies. Rituximab, tocilizumab and to some extent eculizumab have well-known safety profiles for other inflammatory diseases, and rituximab and azathioprine may be safe during pregnancy.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleRecent progress in maintenance treatment of neuromyelitis optica spectrum disorderen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2020 The Authorsen_US
dc.source.journalJournal of Neurologyen_US
dc.identifier.citationJournal of Neurology. 2020en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal